Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

CAMBRIDGE, Mass.--()--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, announced today that management is scheduled to present a company overview at the following investor conferences in November. Chris Garabedian, Sarepta’s president and chief executive officer, will be the presenter.

  • 2014 Deutsche Bank BioFEST in Boston, MA on Monday, December 1, 2014, at 8:05 a.m. EST. The session will be conducted as a fireside chat.
  • Oppenheimer 25th Annual Healthcare Conference in New York, NY on Wednesday, December 10, 2014, at 11:30 a.m. EST.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at www.sarepta.com and will be archived under the events and presentations section following each presentation for 90 days.

About Sarepta Therapeutics

Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward–looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our web site at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Contacts

Sarepta Investor:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media:
Tony Plohoros, 908-940-0135
tplohoros@6degreesPR.com

Contacts

Sarepta Investor:
Stephanie Ascher, 212-362-1200
stephanie@sternir.com
or
Sarepta Media:
Tony Plohoros, 908-940-0135
tplohoros@6degreesPR.com